Drug research

Nogapendekin alfa inbakicept (NAI)

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as ANKTIVA; N-803; Nogapendekin alfa-inbakicept

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
NAI for Sepsis With Persistent LymphopeniaNCT07578558	IBRX	Phase 2	Not yet recruiting	2027-08-03Estimated
NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With SepsisNCT07783789	IBRX	Phase 2	Not yet recruiting	2028-05-12Estimated

IBRXNot yet recruitingPrimary completion: 2027-08-03 · Estimated

Trial details

IBRXNot yet recruitingPrimary completion: 2028-05-12 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.